收费全文 | 113395篇 |
免费 | 44838篇 |
国内免费 | 74篇 |
耳鼻咽喉 | 1850篇 |
儿科学 | 5955篇 |
妇产科学 | 1797篇 |
基础医学 | 20526篇 |
口腔科学 | 5587篇 |
临床医学 | 16976篇 |
内科学 | 28038篇 |
皮肤病学 | 8124篇 |
神经病学 | 17660篇 |
特种医学 | 2974篇 |
外科学 | 17794篇 |
综合类 | 498篇 |
一般理论 | 94篇 |
预防医学 | 9528篇 |
眼科学 | 1953篇 |
药学 | 8158篇 |
中国医学 | 1036篇 |
肿瘤学 | 9759篇 |
2023年 | 612篇 |
2022年 | 431篇 |
2021年 | 2735篇 |
2020年 | 6100篇 |
2019年 | 12317篇 |
2018年 | 11832篇 |
2017年 | 12610篇 |
2016年 | 13223篇 |
2015年 | 13093篇 |
2014年 | 13510篇 |
2013年 | 14542篇 |
2012年 | 7609篇 |
2011年 | 7411篇 |
2010年 | 10466篇 |
2009年 | 6616篇 |
2008年 | 4303篇 |
2007年 | 3298篇 |
2006年 | 2944篇 |
2005年 | 2541篇 |
2004年 | 2322篇 |
2003年 | 1991篇 |
2002年 | 1894篇 |
2001年 | 934篇 |
2000年 | 722篇 |
1999年 | 407篇 |
1998年 | 325篇 |
1997年 | 170篇 |
1996年 | 167篇 |
1995年 | 156篇 |
1994年 | 170篇 |
1993年 | 136篇 |
1992年 | 249篇 |
1991年 | 210篇 |
1990年 | 170篇 |
1989年 | 186篇 |
1988年 | 175篇 |
1987年 | 156篇 |
1986年 | 157篇 |
1985年 | 154篇 |
1984年 | 105篇 |
1983年 | 103篇 |
1982年 | 66篇 |
1981年 | 73篇 |
1980年 | 72篇 |
1979年 | 84篇 |
1978年 | 92篇 |
1977年 | 72篇 |
1976年 | 51篇 |
1973年 | 52篇 |
1972年 | 61篇 |
Background
While drinking alcohol, one must choose between the immediate rewarding effects and the delayed reward of a healthier lifestyle. Individuals differ in their devaluation of a delayed reward based on the time required to receive it, i.e., delay discounting (DD). Previous studies have shown that adolescents discount more steeply than adults and that steeper DD is associated with heavier alcohol use in both groups.Methods
In a large-scale longitudinal study, we investigated whether higher rates of DD are an antecedent or a consequence of alcohol use during adolescent development. As part of the IMAGEN project, 2220 adolescents completed the Monetary Choice Questionnaire as a DD measure, the Alcohol Use Disorders Identification Test, and the Timeline Follow Back interview at ages 14, 16, 18, and 22. Bivariate latent growth curve models were applied to investigate the relationship between DD and drinking. To explore the consequences of drinking, we computed the cumulative alcohol consumption and correlated it with the development of discounting. A subsample of 221 participants completed an intertemporal choice task (iTeCh) during functional magnetic resonance imaging at ages 14, 16, and 18. Repeated-measures ANOVA was used to differentiate between high-risk and low-risk drinkers on the development of neural processing during intertemporal choices.Results
Overall, high rates of DD at age 14 predicted a greater increase in drinking over 8 years. In contrast, on average, moderate alcohol use did not affect DD from ages 14 to 22. Of note, we found indicators for less brain activity in top-down control areas during intertemporal choices in the participants who drank more.Conclusions
Steep DD was shown to be a predictor rather than a consequence of alcohol use in low-level drinking adolescents. Important considerations for future longitudinal studies are the sampling strategies to be used and the reliability of the assessments.Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献